ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 2037

Poor Quality of Gout Care Is Strongly Associated with Higher Gout-Related Health Care Utilization

Jasvinder A. Singh1 and Joshua Richman2, 1Department of Medicine, University of Alabama, Tuscaloosa, AL, 2Biostatistics, UAB School of Medicine, Birmingham, AL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: gout, Outcome measures, quality of care, uric acid and utilization review

Session Information

Title: Quality Measures and Innovations in Practice Management and Care Delivery

Session Type: Abstract Submissions (ACR)

Background/Purpose:  

Proponents of improving quality of gout care have suggested various gout quality indicators, but no study to date has shown the link between good quality care and improved outcomes. The aim of the study was to assess  whether appropriate good quality care for gout, including uninterrupted urate-lowering therapy (ULT) and achievement of target serum urate <6 mg/dl, is associated with reduced gout-related utilization.

Methods:

This retrospective study utilized the Veterans Affairs (VA) administrative and clinical databases claims from fiscal years 2002 to 2010, using the presence of an International Classification of Diseases, ninth revision (ICD-9) code, 274.xx in a VA outpatient or inpatient visit to define the gout cohort.  A 90-day or longer filled VA prescription for allopurinol, probenecid or febuxostat in a patient with gout was considered as exposure to ULT.  The two independent predictors of interest were Medication Possession Ratios (MPRs) for each ULT and achievement of target sUA < 6 mg/dl.  The MPR denominator was the number of days from index to the exhaustion of the last prescription and the numerator was days of medication supplied over that period from first to last prescription. We used regression analyses with a quasi-Poisson distribution given the type of data, limiting the analyses to patients with >=1-year of follow-up.  The outcome was counts of visits with an offset for the number of years in the cohort. 

Results:

The gout cohort consisted of 376,421 patients with mean age 70 years, 99% were male and 61% were married.  Their exposure to various medications for the treatment of gout was as follows: allopurinol, 70%; febuxostat, 0.3%; and probenecid, 3%.  Mean follow-up was 6.2 years (standard deviation, 2.9). Higher MPRs for allopurinol, febuxostat, and probenecid were associated with significantly lower outpatient, urgent care, emergency room and overall visits (all p-values <0.0001; Table 1).  Achievement of target sUA < 6 mg/dl was associated with significantly lower gout-related outpatient, inpatient, urgent care and emergency room visits (all p-values <0.012; Table 1).  Conversely, a higher proportion of sUA levels >=6 mg/dl was associated with higher gout-related outpatient, inpatient, urgent care and emergency room visits (all p-values <0.00001).

Table 1. Association of MPR for three ULTs and of achievement of target sUA < 6mg/dl with future gout-related health care utilization

 

Incidence rate ratio* [p-value]

 

Any visit

Outpatient visit

ER visit

Urgent care

Inpatient

Adherence to ULT

 

 

 

 

 

Allopurinol MPR (n=231,131)

0.50

[p<0.00001]

0.50

[p<0.00001]

0.32

[p<0.00001]

0.38

[p<0.00001]

0.80

[p=0.00005]

Febuxostat MPR (n=759)

0.64

[p=0.0031]

0.66

[p=0.0074]

0.38

[p=0.00073]

0.28

[p=0.0078]

0.85

[p=0.661]

Probenecid MPR (n=10,514)

0.47

[p<0.00001]

0.47

[p<0.00001]

0.45

[p<0.00001]

0.40

[p=0.00374]

0.89

[p=0.63]

 

 

 

 

 

 

Achieving target sUA

 

 

 

 

 

Any sUA <6 mg/dl (n=161,069)

0.99

[p=0.11]

1.02

[p=0.0116]

0.79

[p<0.00001]

0.57

[p<0.00001]

0.90

[p=0.0105]

Proportion of sUA levels >=6 mg/dl (n=161,069)

1.72

[p<0.00001]

1.62

[p<0.00001]

2.43

[p<0.00001]

4.05

[p<0.00001]

2.87

[p<0.00001]

*Incidence rate ratio for each outcome is for patients with MPR of 1 versus 0

Conclusion:

This is the first study to find evidence of association of poor quality of care (lower ULT MPR and non-achievement of target sUA) with greater gout-related health care utilization, especially for emergency room and urgent care visits.  Improvement in quality of gout care may reduce expensive gout-related utilization of emergency room and urgent care resources.


Disclosure:

J. A. Singh,

research and travel grants from Takeda, Savient, Wyeth and Amgen,

2,

J.A.S. has received speaker honoraria from Abbott,

9,

; aConsultant fees from URL pharmaceuticals, Savient, Takeda, Ardea, Allergan and Novartis.,

5;

J. Richman,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/poor-quality-of-gout-care-is-strongly-associated-with-higher-gout-related-health-care-utilization/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology